Form 8-K Esperion Therapeutics, For: Aug 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy; Shares Will Rebound
August 10, 2015 7:08 AM EDTNeedham & Company upgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Strong Buy with a price target of $130.00.
Analyst Chan Messer commented, "ESPR shares have recently pulled back over regulatory concerns. Some investors feel that an evolution of thinking at the FDA about... More
Chardan Capital Trims PT on Esperion (ESPR) Following Q2 Results, TAK-475 Failure Concerning for ETC-1002
August 7, 2015 8:30 AM EDTChardan Capital affirms its Sell rating on Esperion (Nasdaq: ESPR) and cuts its price target from $45 to $40 following Q2 results.
Analyst Gbola Amusa commented, Esperion reported 2Q basic and diluted EPS of -$0.55, versus our expectation of -$0.56. A share count of... More
